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Background/Aim. Switching the patient from one pharmaceutical formulation of the same
drug to another,  may lead to therapeutic inadequancy in some cases. To minimize the risk,
careful pharmacokinetic studies are desired in the pre-registration period and afterwards.
Methods. A randomized, crossover design with one-week wash-out period between each dose
was applied. Serum samples, obtained before dosing and at various appropriate time points
up to 15 hours, were analyzed for nimesulide content by a high-performance liquid chroma-
tographic method with ultraviolet (UV) detection. The pharmacokinetics and relative bio-
availability of three different pharmaceutical formulations containing nimesulide, manufac-
tured by the same pharmaceutical factory, were studied prospectively in 12 healthy subjects of
both sexes. A single 100-mg oral dose of nimesulide was given to the volunteers in the form of
conventional tablets, mouth dissolving tablets or as a suspension. Analysis of variance, power
analysis, 90% confidence intervals, and two one-sided tests were used for the statistical analy-
sis of pharmacokinetic parameters. Results. The tolerability of all preparations was excellent.
The respective confidence intervals of the ratios of geometric means of Cmax and AUC
0-∝ of
nimesulide were out of acceptable limits either for conventional tablets in comparison with
suspension or for mouth dissolving tablets when compared with conventional tablets. A com-
parison of mouth dissolving tablets with suspension showed a statistically significant differ-
ence between Cmax values (suprabioavailability of mouth dissolving tablets), while the point
estimate of the ratio of geometric means of AUC
0-∝ was 0.945 with the corresponding 90%
confidence interval of 0.902−0.991. At the 5% level of significance, there were no differences
between the formulations under the study in times elapsed to peak serum concentrations, as
revealed by the non-parametric Wilcoxon signed ranks test. Conclusion. Only a 90% confi-
dence interval for the relative differences of log-transformed AUC
0-∝ values of nimesulide ab-
sorbed from mouth dissolving tablets vs. suspension was included in the 80% to 125% interval
proposed by the Food and Drug Administration (FDA). On that basis, mouth dissolving tab-
lets (Nimulid-MD™) were considered bioequivalent to Nimulid™ suspension according to the
extent of drug absorption. Concerning the comparable amounts of nimesulide available in the
systemic circulation after application of these formulations the one might not expect thera-
peutic failure after switching the patient from one to another.
K e y   w o r d s : anti-inflammatory agents, non-steroidal; chemistry,
pharmaceutical; dose-responce relationship, drug;
pharmacokinetics; biological availability; therapeutic
equivalency.
Introduction
Nimesulide is a synthetic sulfonanilide derivative. It
belongs to a class of non-steroidal anti-inflammatory drugs
(NSAID) which selectively inhibit cyclooxygenase-2 but,
also, interfere with the production/action of mediators other
than prostaglandins such as enzymes, toxic oxygen deriva-
tives, cytokines, platelet-activating factor and histamine (1,Страна 888 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 12
2). A combination of a variety of mechanisms makes nime-
sulide a NSAID with marked anti-inflammatory, analgesic
and antipyretic activities (2, 3). Several recent experimental
studies have also demonstrated a significant neuroprotective
effect of nimesulide on chronic cerebral hypoperfusion (4),
global cerebral ischemia (5,6), diffuse traumatic brain injury
(7, 8) or cerebral infarction induced by permanent middle
cerebral artery occlusion (9).
The pharmacokinetic profile of orally administered
nimesulide is characterized by rapid and complete absorp-
tion, the rate and the extent of which do not differ signifi-
cantly whether the drug was administered in a tablet or in a
suspension form. The time to reach maximal concentration
was reported to vary from 1.9h in children to more than
2.5h in healthy volunteers (3).
Nimesulide is 99% bound to human plasma proteins,
mainly albumins and it is principally distributed in the extra-
cellular fluid compartment. The drug undergoes extensive
metabolism in the liver. Metabolic biotransformation can oc-
cur at both the phenoxy ring moiety and the aromatic nitro
group. The principal metabolite is 4-hydroxynimesulide,
which contributes to the anti-inflammatory activity of the
compound. Another degradation product, 2-(4’-hidroxyphe-
noxy)-4-N-acetylamino-methansulfonanilide, was recently
identified in human urine and it is produced in much lower
concentrations.
Only 1% to 3% of the dose is excreted unchanged in
the urine, while the metabolites are eliminated mainly via
the urine (70%) or the feces (20%) in both free and conju-
gated form. The terminal elimination half-life of nimesulide
is shorter in children than in adults (approx. 2.4h vs. up to
5h) while the elimination half-times of metabolites are
nearly 2-times higher than that of the parent compound (3).
The purpose of this study was to evaluate the toler-
ability, pharmacokinetic property and comparative bioavail-
ability of the three different pharmaceutical formulations of
nimesulide, all manufactured by the drug company Panacea
Biotec Ltd. from India, that are available at the Serbian
market. Particular attention has been made to the pharma-
cokinetic profile of flavoured dispersible tablets (MD tab-
lets) with fast mouth dissolving characteristics thereby pro-
viding immediate relief of the drug (10). Although this had
not been a classic bioequivalence study, it was of therapeu-
tic interest to compare their bioavailability with that of the
liquid formulation (suspension) which is usually thought to
be a 100% bioavailable.
Methods
A single-dose, open-label, randomized, six-sequence,
three-period crossover study design was used to evaluate
the bioavailability of nimesulide, prepared either as a 100-
mg
 conventional tablets (Nimulid™ tablets), 100-mg mouth
dissolving tablets (Nimulid-MD™ tablets) or a 50 mg/5 ml
suspension (Nimulid™ suspension). Twelve subjects of
both sexes in good  physical condition, as determined by the
complete medical and laboratory examinations before the
study,  were enrolled and provided written informed consent
prior to any study related procedure. The study was ap-
proved by the Drug Commission and the Ethics Committee
of the Military Medical Academy, on September 20, 2001.
 The enrolled subjects were randomly assigned to one of
the six sequence groups such that upon the completion of the
study each subject received all three regimens. Dosing in each
of the three consecutive periods was separated by 7-day wash-
out period. A single dose of 100 mg nimesulide (one conven-
tional tablet, one MD tablet or a 10-ml volume of suspension)
was given with 200 ml of non-carbonated mineral water fol-
lowing an overnight fast of at least 10 hours.
Venous blood samples (approx. 8 ml) were collected
prior to dosing (hour 0) and afterwards at time-points 0.33,
0.66, 1, 1.5, 2, 3, 4, 6, 8, 12 and 15 hours. The samples were
centifuged within one hour of collection and the serum was
separated and frozen at -20°C until assayed.
Assay method
The High Performance Liquid Chromatography
(HPLC) set was equipped with a pump (Model 2150, LKB,
Bromma, Sweden), an automatic sample system (Model
AS-100, Bio-Rad Laboratories, Inc., Hercules, CA, USA), a
variable wavelength UV detector (Model 1801, Bio-Rad
Laboratories, Inc., Hercules, CA, USA) and an integrator
(Model 2221, LKB, Bromma, Sweden). For the acquisition
and integration of analytical data, a Bio-Rad Value Chrom
™
software, operated by Pentium microprocessor, was used.
Separations were performed on a reverse phase column
(BioSil C18 HL, 4.6 x 250 mm; Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) at the ambient temperature.
The HPLC assay for determination of unchanged
nimesulide was fully developed and completely validated in
our laboratory. Its development, however, had been based
on the data published by Gupta (11) but due to differences
in the equipment and materials being on disposal, it had to
be generally modified.
The HPLC analysis was performed by using a mobile
phase consisted of 0.01M ammonium-dihydrogen-orthopho-
sphate and acetonitrile (1:1), previously filtrated and de-
gassed by a membrane degasser. The flow rate was 1.0
ml/min, an injector loop volume was 20 μl, and an UV de-
tector wavelength set at 300 nm throughout the assay. Un-
der these conditions the retention time of nimesulide was
about 6.47 min. All the chemicals were of HPLC, and p.a.
purity, and had been purchased commercially.
After being refrigerated, the samples were allowed to
melt spontaneously at room temperature. Aliquots of 0.5 ml of
serum were dispensed into glass tubes and were deproteinized
using 0.5 ml of acetonitrile. The mixture was strongly vortexed
for 60 seconds to ensure adequate mixing and afterwards cen-
trifuged at 8000 g for 2 minutes. The obtained supernatant
amounting 20-μl was injected into the HPLC system and fur-
ther analyzed using the validated HPLC-UV method. Standard
solutions (range of concentrations 0.05−10.0 µg/ml) andБрој 12 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Страна 889
spiked serum samples (range of concentrations 0.1−5.0 µg/ml)
were also determined under the same assay conditions.
Pharmacokinetic analysis
The pharmacokinetic parameters of nimesulide were
estimated using non-compartmental techniques. The peak
plasma concentration (Cmax) and the time elapsed to peak
concentration (tmax) were obtained directly from the data.
The elimination rate constant (ke) was obtained from the
slope of the terminal log-linear phase of the semilog plot of
concentration versus time. Half-life (t1/2) was calculated as
ln2/ke (ln2 = 0.693). The area under the nimesulide serum
concentration-time curve (AUC
0-15) was computed using the
linear trapezoidal rule while the area under the serum con-
centration-time curve from time 0 to the infinite time
(AUC
0-∝) was calculated as the sum of AUC
0-15 and Ct/ke,
where t was the time of the last measurable concentration
(Ct) and ke was the elimination rate constant.
Parameters Cmax, tmax and AUC
0-∝ were accepted as the
main variables, while the values of AUC
0-15, residual areas
[AUC
0-15/AUC
0-∝ * 100], ke and t1/2 served as the secondary
pharmacokinetic objectives.
Statistical analysis
The following main pharmacokinetic parameters,
which completely describe the rate and the extent of ab-
sorption of nimesulide, derived from the individual serum
concentration-time profiles were subjected to statistical
analysis: Cmax, AUC
0-∝ and tmax. The comparison of secon-
dary kinetic variables was only descriptive.
Following logarithmic transformation of AUC
0-∝ and
Cmax the values were subjected to analysis of variance
(ANOVA) including terms for subjects, treatment (se-
quence) and period. For evaluation of bioequivalence the
point estimates and 90% confidence intervals for the dif-
ference between test and reference formulations were con-
structed using the residual mean square error, obtained
from the multifactorial ANOVA. The point estimates and
the 90% confidence intervals were then back transformed
to give estimates of the ratio of the geometric means and
the corresponding 90% confidence intervals for the ratios
of the two formulations in the comparison. A non-
parametric test (Wilcoxon Signed Rank's Test) was per-
formed for tmax.
Bioequivalence between the formulations was ac-
cepted if the back transformed 90% confidence intervals for
the geometric mean ratios od AUC
0-∝ and Cmax had follen
within 0.80–1.25 range (12−14) and if the differences in tmax
between the two formulations had been not statistically dif-
ferent (p > 0.05).
Results
HPLC method
Under the described assay conditions, linearity was
observed in serum standard curves of nimesulide over the
range of 0.05 – 10.0 µg/ml with a correlation coefficient
greater than 0.999. The lower limit of quantification (LOQ)
of unchanged nimesulide was 0.1 µg/ml while the limit of
detection was 0.05 µg/ml of serum. Concentrations below
LOQ were reported as 0.0 µg/ml. The mean recovery of ex-
traction of nimesulide from serum samples ranged from
93% to 109%. The same working standard solutions had been
stable during a 5-day working period when kept in the refrig-
erator.
Study in healthy volunteers
A total of 12 subjects, whose demographic character-
istics are summarized in Table 1, were selected to partici-
pate in the study. There were no differences in their age,
weight or height that might compromise the validity of the
planned pharmacokinetic trial.
The mean serum concentration-time profile of nime-
sulide absorbed from the 3 different pharmaceutical prepa-
rations is shown in Figure 1. Marked differences were ob-
served between the amounts of drug that had reached the
systemic circulation during the period of 15 hours. How-
ever, the tolerability of all three preparations containing
nimesulide was reported as excellent.
The relevant pharmacokinetic parameters of nimesulide
for each preparation are listed in Table 2. As it can be seen,
the residual area (relation between AUC
0-15 and AUC
0-∝) of
nimesulide (7.3% suspension, 5.5% conventional tablets,
5.0% MD tablets) accounted for less than 20% of the area
from time 0 to the time of the last measurable concentration.
Therefore, the stated criterion (AUC
0-15/AUC
0-∝ * 100 > 80%)
was fulfilled and the residual area had no sizeable impact on
the calculation of AUC
0-∝ and, thus, on bioavailability.
Table 1
Demographic data of subjects (n = 12)
Age (years) Weight (kg) Height (cm)
Mean* 37.3 88.0 178.8
SE
† 2.7 5.9 2.7
Min. 21.0 60.0 160.0
Max. 49.0 110.0 191.0
CV
‡ (%) 25.2 23.2 5.3
Males, n  = 9 Females, n = 3
*Mean – arithmetic mean, 
†SE – standard error of the mean, 
‡ CV – coefficient of variationСтрана 890 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 12
Fig. 1 − Mean (±SE) concentration vs. time profiles of nime-
sulide in serum after oral administration of a 100-mg dose of
suspension Nimulid
TM, conventional tablets Nimulid
TM or Ni-
mulid-MD
TM tablets to 12 healthy volunteers of booth sexes.
The rate of nimesulide absorption from the tested
pharmaceutical formulations, as well as their half-lives of
the terminal phase, agreed very well after the application of
the three nimesulide-containing preparations. Marked dif-
ferences in the maximal concentrations were noted between
MD tablets and the other two formulations following the
same dosages of the drug.
The statistical evaluation of the main pharmacokinetic
variables, which describe the rate and the amount of ab-
sorption of nimesulide, is presented in Table 3. The respec-
tive point estimates of the ratios of geometric means of log-
transformed Cmax and AUC
0-∝ of nimesulide were 0.655 and
0.498 (conventional tablets vs. suspension), 1.244 and 0.945
(MD tablets vs. suspension), and 1.827 and 2.103 (MD tab-
lets vs. conventional tablets). The corresponding 90% con-
fidence intervals were 0.260−0.607, 0.335−0.603,
1.004−1.542, 0.902-0.991, 1.358−2.457 and 1.575−2.810,
respectively. For the median tmax values, at a 5% level of
significance, there were no significant differences between
the formulations in the study, as revealed by the non-
parametric Wilcoxon signed ranks test.
Table 2
*Mean (± SE)
† values of pharmacokinetic parameters of nimesulide after the ingestion of a single 100-mg dose of conventional
tablets Nimulid™, mouth dissolving tablets Nimulid-MD™ and suspension Nimulid™
F o r m u l a t i o n
Suspension Conventional tablets MD tablets Parameter
Mean SE Mean SE Mean SE
Cmax (µg.ml
-1)  4.53 0.67  4.11 1.03  5.88 0.98
tmax (h)  3.0 0.4  2.8 0.5  2.8 0.3
ke (h
-1)  0.2214 0.0201  0.2764 0.0327  0.2645 0.0318
t1/2 (h)  3.5 0.4  2.8 0.2  3.0 0.3
AUC
0-15 (µg.h.ml
-1) 34.75 6.55 24.70 8.09 33.86 6.17
AUC
0-∞ (µg.h.ml
-1) 38.44 7.55 26.56 8.95 36.01 6.80
Residual area (%)  7.3 1.7   5.5 1.5  5.0 1.3
* Mean – arithmetic mean, 
†SE – standard error of the mean
Table 3
Statistical evaluation of bioequivalence of nimesulide from the Nimulid™ 100-mg conventional tablets, Nimulid-MD™ 100-mg
mouth dissolving tablets or Nimulid™ suspension (50-mg/5 ml)
Pharmacokinetic parameter Statistical test
Cmax AUC
0-∞ tmax
Nimulid™ tablets vs. Nimulid™ suspension
Point estimate of the  ratio of geometric means 0.655 0.498 –
90% confidence interval of the ratio of geometric
means*
0.260 − 0.607 0.335 − 0.603 –
Wilcoxon signed ranks test
† – – p = 0.5465
Nimulid-MD™ tablets vs. Nimulid™ suspension
Point estimate of the  ratio of geometric means 1.244 0.945 –
90% confidence interval of the ratio of geometric
means*
1.004 – 1.542 0.902 – 0.991 –
Wilcoxon signed ranks test
† – – p = 0.5050
Nimulid-MD™ tablets vs. Nimulid™ tablets
Point estimate of the  ratio of geometric means 1.827 2.103 –
90% confidence interval of the ratio of geometric
means*
1.358 – 2.457 1.575 – 2.810 –
Wilcoxon signed ranks test
† – – p = 0.7518
*   - Acceptance range (bioequivalence): 0.80 – 1.25
† - Bioequivalence: p > 0.05Број 12 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Страна 891
Discussion
The analysis of the assay data indicated that the chosen
HPLC-UV method was simple, precise and enough accurate
for performing a valid bioequivalence study. According to
the literature, its sensitivity was comparable to the results of
the HPLC methodologies that had been applied so far to
determine nimesulide concentration by other investigators
(15−20). As expected, however, the HPLC method we used
was less sensitive than liquid chromatography coupled to
tandem mass spectrometry (21).
Twelve subjects were arbitrarily chosen to participate
into the study. That number corresponded to the smallest
sample that is accepted as sufficient to assess bioequiva-
lence (22, 23) and might represent a reliable number of par-
ticipants for the bioequivalence decision. The post-study
calculations based on the log-ANOVA error data [AUC
0-∝
CV-intra = 6.68%; suspension vs. MD tablets] revealed a
sample size of 7 subjects to be quite enough to show the dif-
ference of 20% between the AUC
0-∝ values of the test and
the reference articles. The type I and type II errors would
not exceed 5% and 20%, respectively.
The overall pharmacokinetic profile of nimesulide in
the present study, independently from the pharmaceutical
formulation being used, was close and in agreement with
the data previously published for oral nimesulide prepara-
tions in the relevant publications (3, 15−18, 24−29). How-
ever, on the basis of maximum serum concentrations and
AUC
0-∝ values of nimesulide it was concluded that they had
been significantly different after the administration of sus-
pension and conventional tablets. Oppositely, the total
amount of nimesulide (AUC
0-∝) absorbed from the suspen-
sion and MD tablets did not differ significantly with the
power (derived from ANOVA) greater than 0.999.
Only 90% confidence intervals for AUC
0-∝ geometric
mean ratios of MD tablets, when compared to suspension,
were included in the 80% to 125% interval proposed by the
U.S. Food and Drug Administration (12, 13) and the differ-
ence between tmax values was statistically insignificant. On
that basis, tablets Nimulid-MD™ were considered bioe-
quivalent to suspension Nimulid™ according to the extent of
absorption of nimesulide. The differences in Cmax values,
indicating suprabioavailability of MD tablets according to
the rate of absorption, were judged not to be therapeutically
important since, nimesulide is not a medicine which phar-
macodynamic action is closely related to the level of maxi-
mal concentrations in the blood.
Conclusion
From the pharmacokinetic point of view, concerning the
total amount of drug that is available at the site of action, sus-
pension and MD tablets could be marked as interchangeable
by a physician and might not be expected to produce thera-
peutic failure after switching the patient from one to another.
An increased maximal concentration in the serum after MD
tablets would definitely not increase the toxicity level of
nimesulide due to its wide therapeutic window in patients.
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FARMAKOKINETIČKO POREĐENJE TRI FARMACEUTSKA OBLIKA
NIMESULIDA KOD ZDRAVIH DOBROVOLJACA
Uvod/Cilj. Prevođenje bolesnika sa jednog na drugi farmaceutski oblik istog leka,
može u pojedinim slučajevima, rezultirati promenjenim terapijskim efektom. U cilju
smanjenja ovakvih rizika, u preregistracionom periodu, ali i nakon puštanja u pro-
met leka, nužno je sprovesti ozbiljna farmakokinetička ispitivanja. Metode. Izvede-
no je randomizovano i unakrsno ispitivanje sa „wash-out“ periodom od sedam da-
na. Uzorci seruma uzimani su pre davanja lekova, a nakon toga, u definisanim
vremenskim tačkama, tokom 15 sati. Prospektivna studija obuhvatila je 12 zdravih
osoba oba pola u cilju ispitivanja farmakokinetike i relativne biološke raspoloživosti
nimesulida primenjenog u tri različita farmaceutska oblika, koje proizvodi isti proiz-
vođač. Dobrovoljcima je davana jednokratna doza nimesulida od 100 mg, u obliku
standardnih tableta, tableta koje se tope u ustima ili suspenzije. Određivanje nime-Број 12 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Страна 893
sulida vršeno je tečnom hromatografijom visoke rezolucije sa UV detekcijom. Za
statističku analizu izračunatih farmakokinetičkih parametara korišćene su: analiza
varijanse, „power“ analiza, 90% intervali poverenja i dvostruki,  jednostrani t-test.
Rezultati. Podnošljivost svih ispitivanih farmaceutskih oblika nimesulida bila je od-
lična. Kod standardnih tableta, u poređenju sa suspenzijom, ili tableta koje se tope
u ustima, u poređenju sa standardnim tabletama, izračunati intervali poverenja za
relativne razlike logaritamski transformisanih vrednosti maksimalnih koncentracija i
površina ispod krive bili su van definisanih, i stručno prihvaćenih granica. Poređe-
nje bitnih farmakokinetičkih parametara za tablete koje se tope u ustima i suspen-
ziju ukazalo je na statistički značajne razlike među vrednostima maksimalnih kon-
centracija („supra“ biološka raspoloživost tableta koje se tope u ustima), dok je kri-
tična vrednost odnosa geometrijskih sredina niza logaritamski transformisanih vre-
dnosti površina ispod krive iznosila 0,945, a odgovarajući 90% interval poverenja
kretao se u rasponu od 0,902 do 0,991. Pri nivou značajnosti od 5%, primenom
neparametrijskog Wilcoxonovog testa suma rangova, među ispitivanim farmaceut-
skim oblicima nimesulida nisu ustanovljene razlike u vremenima potrebnim da se
dostigne maksimalna koncentracija leka u krvi. Zaključak. Analiza dobijenih rezul-
tata pokazala je da je jedino 90% interval poverenja za relativne razlike logaritam-
ski transformisanih vrednosti površina ispod krive nimesulida apsorbovanog iz tab-
leta koje se tope u ustima, u poređenju sa suspenzijom, bio uključen u raspon
80−125%, koji prihvata Agencija za hranu i lekove SAD. Stoga je donet zaključak
da su samo tablete koje se tope u ustima (Nimulid-MD™), ceneći ukupnu količinu
leka koja je dospela u sistemsku cirkulaciju, biološki ekvivalentne formulaciji koja,
po definiciji, ima apsolutnu biološku iskoristljivost (Nimulid™ suspenzija). Pod na-
vedenim uslovima ne mogu se očekivati promene u terapijskoj efikasnosti tokom
prevođenja bolesnika sa jednog na drugi farmaceutski oblik nimesulida.
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